Law360, New York (June 24, 2009, 12:00 AM ET) -- In response to Federal Trade Commission Chairman Jon Leibowitz's claims that banning "pay-for-delay" patent settlements between generics and branded drugmakers would save consumers $3.5 billion a year, leading generics maker Teva Pharmaceuticals USA decried the supposed savings as based on a "flawed assumption."
Teva said in a statement Wednesday that the company was "astonished" by Leibowitz's statement, and maintained that the settlements, in which branded-drug makers pay generics manufacturers to delay entry into the market, actually save consumers billions of dollars.
The FTC's analysis of pay-for-delay...
Teva Blasts FTC's Position On Pay-For-Delay
To view the full article, take a free trial now.
